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Abstract 
In this paper we examine biotechnology innovation in Canada. We make a profile 
description of Canadian biotechnology in the 12 most important agglomerations in terms 
of patenting quality and quantity, the nature of biotechnology activities, the properties of 
the assignees and their propensity to collaborate. The analysis of patent-owning 
organizations reveals a crucial role of the publicly funded research in Canadian 
biotechnology. We identify and compare the importance of well developed intellectual 
property policies and functioning technology transfer offices at universities. We find 
evidence of only very little cooperation that would result in the co-assignment of the 
intellectual property among organizations.  
Keywords: intellectual property, patents, assignee, cluster, innovation, biotechnology 
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1. Introduction 
Canada has a small population dispersed over a large geographical area and its 
private sector is dominated by small and medium sized companies. As a consequence, 
research and development has to concentrate in geographical agglomerations and 
clusters1 in order to contribute to an efficient innovation system2. The context of this 
study is the biotechnology sector, which should presumably benefit from the types of 
knowledge spillovers3 and information exchanges that are facilitated by spatial clustering. 
Niosi and Bas (2001) find that biotechnology activity in Canada is indeed clustered and is 
mainly concentrated in three large cities – Toronto, Montreal and Vancouver, where most 
patents and venture capital are located. Niosi and Bas note that clusters have also 
developed around medium-sized urban agglomerations, such as Ottawa, Edmonton, and 
Calgary, or specialized clusters around some smaller cities. They also argue that it is the 
population of the metropolitan area and the local university research, which are the key 
factors explaining the size, location and characteristics of these clusters. They identify 
universities, government laboratories and a few large firms as the main anchor tenants in 
Canadian biotechnology clusters. Aharonson et al. (2004) argue that, in Canada, clustered 
biotechnology companies are eight times more innovative than the ones that are remotely 
located. The largest effects were observed for firms located in clusters strong in their own 
specialization. Niosi and Banik (2001) also find that biotechnology companies in the 
clusters of Montreal, Toronto and Vancouver perform better than companies outside 
these clusters. 
                                                
1 A cluster is defined by Porter (1998) as a geographic concentration of interconnected companies, 
specialised suppliers, service providers, firms in related industries, and associated institutions (for example, 
universities, standards agencies, and trade associations) in particular fields that compete but also co-
operate. 
2 The reason behind the agglomeration of innovative activities is the fact that geographical proximity 
facilitates knowledge sharing, since knowledge does not spill over large distances (Audretsch and Feldman, 
1996; Jaffe and Trajtenberg, 1996). 
3 Localized knowledge spillovers are defined as knowledge externalities bounded in space that allow 
companies operating nearby key knowledge sources to introduce innovations at a faster rate than rival firms 
located elsewhere (Breschi and Lissoni, 2001) 
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Another line of research aims at shedding light on the determinants of differential 
growth in biotechnology companies in Canada. It is often argued that alliances and 
cooperation are an indispensable element in the success of small firms. Niosi (2003) 
suggests that international alliances with large pharmaceutical corporations are the main 
determinant of growth in Canadian biotechnology and that timely alliances are also the 
critical key factor for the survival of the new biotech firms. Oliver (1994) empirically 
confirms that this inability of a new biotechnology company to form inter-firm alliances 
is associated with organizational death. Niosi (2003) however argues that the success at 
forging suitable alliances alone does not sufficiently explain differential growth in 
biotechnology companies. He adds that the quantity of patents, the amount of venture 
capital, the size of exports and the specialization in human health products play an 
extremely important role as well. Queenton and Niosi (2003) propose two other 
determinants of rapid growth: the quality of patents and the presence of star scientists in 
biotechnology firms. According to them, Canadian biotechnology clusters are strongly 
related to high-class academic research and star scientists working in universities. Their 
study also highlights the importance of geographical proximity of star scientists for 
obtaining venture capital, and for starting and growing biotechnology firms. It was also 
confirmed that in Canada many of the star scientists capitalise on their knowledge 
through firm start-ups. One third of Canadian biotechnology firms are estimated to be 
university spin-offs (Niosi, 2003). 
In summary, growth and continued health of Canadian biotechnology clusters are 
dependent upon the presence of major attractors such as research universities and 
governmental laboratories active in biotechnology, innovative propensity of the local 
scientists (i.e., the existence of star scientists), formation of alliances and active 
cooperation among biotechnology firms, composition of biotechnology fields in the 
cluster (i.e., the focus on the health-related products) and presence of the largely 
innovative biotechnology firms (with patents of a high quality and quantity). This paper 
intends to address most of the above factors. It aims at understanding the creation of 
biotechnology innovation in Canada and its main objective is to identify, analyze and 
describe potential Canadian biotechnology clusters based on the characterization of the 
quality and quantity of their innovative outputs, the nature of biotechnology activities 
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which are carried out in these locations, the characteristics of the patent-owning entities 
and their propensity to collaborate. Our major contribution lies in embracing a cluster 
approach, i.e., all analyses are made at the cluster level (all properties and characteristics 
are calculated per cluster). Most of the studies providing a descriptive profile of 
innovation in Canadian biotechnology are carried out and presented at either the province 
or firm level, with some notable exceptions, such as Aharonson et al. (2008) whose micro 
clusters are at the forward sorting area (FSA) level. In their paper on the factors 
influencing the relative productivity of different locations they show that agglomeration 
effects take place mainly at the level of local neighbourhoods. However, the goal of our 
study is not to examine the innovativeness of locations at such low level of aggregation, 
but to give a broader picture of patent ownership in Canadian biotechnology. We are 
seeking to identify and characterize potential biotechnology clusters in the Porter sense, 
and to complete the full picture of Canadian biotechnology innovation by including all of 
the biotechnology agglomerations in Canada. Previous cluster-based papers have focused 
mainly on two or three major Canadian biotechnology clusters, but little is known about 
the smaller concentrations, which are less active in biotechnology. Finally, we base our 
study on the complete database of all the Canadian biotechnology patents registered with 
the United States Patents and Trademarks Office (USPTO), which no other study to our 
knowledge has done so far. Previous researchers usually adopted the approach of 
analyzing only representative samples. 
The paper is organised as follows: section 2 introduces the methodology and the data 
used in this study, section 3 presents the results regarding the biotechnology patents and 
their assignees, the composition of the biotech activities, the inventors and their 
collaborative behaviour and section 4 concludes.  
2. Methodology 
Patents have long been used as innovation measures and as indicators of 
developments in many industrial sectors. As a result of the high propensity to patent in 
biotechnology, patents are considered to be good indicators of the innovative productivity 
of biotech companies. The patent database used for the empirical analysis is the USPTO 
database. This is the only patent database which provides the geographical location of the 
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residence of each inventor. The use of the USPTO database instead of the CIPO may 
cause a certain bias in the data, which we consider minimal, since Canadian inventors 
usually patent both in Canada and in the US. The much larger and easily accessible 
American biotechnology market offers them a greater potential than the biotechnology 
market in Canada.  
Biotechnology encompasses several different research technologies and several 
fields of application. We have opted to base our USPTO search strategy on the OECD 
definition of biotechnology, which is based on the group of carefully selected 
International Patent Codes (IPC)4. An automated extraction program was used to collect 
the required information5 from biotechnology patents. All biotechnology patents granted 
before March 31, 2007 are included. According to the above definition, there are around 
100 000 biotechnology patents registered at the USPTO. We created a patent database, 
which contains all the patents for which at least one inventor resides in Canada and which 
comprises 3550 patents.  
3. Results 
3.1 Canadian biotechnology clusters 
Our clusters are defined as a geographically continuous region active in 
biotechnology (as measured by patent production). We do not measure all the interactions 
between organizations and entities that compose a cluster, and as such, our clusters are 
cities or greater metropolitan areas that are potential cluster candidates in the Porter 
sense. For instance, our clusters for the largest Canadian cities are the Greater Montreal, 
Toronto and Vancouver areas. Regarding the smaller clusters, these are defined as 
agglomerations with some innovative activity in biotechnology (min 15 patents). A 
                                                
4 The OECD definition of biotechnology patents covers the following IPC classes: A01H1/00, A01H4/00, 
A61K38/00, A61K39/00, A61K48/00, C02F3/34, C07G(11/00, 13/00, 15/00), C07K(4/00, 14/00, 16/00, 
17/00, 19/00), C12M, C12N, C12P, C12Q, C12S, G01N27/327, G01N33/(53*, 54*, 55*, 57*, 68, 74, 76, 
78, 88, 92). 
5 Extracted information includes: patent number, the names and addresses of the assignees (patent owners) 
and inventors, the years of patent application and patent granting, the number of claims each patent makes, 
the abstract, all the patent codes and the keywords. 
 12 
summary of the basic statistics regarding the 12 identified clusters defined in such a way 
are presented in Table 1. 
(Insert Table 1 here) 
The Greater Toronto area cluster decisively leads in the number of Canadian 
biotechnology patents; it has almost twice the number of patents of Montreal, which in 
turn has almost twice as many patents as Vancouver. Even Ottawa has more patents than 
an important biotechnology cluster such as Vancouver. Most of the biotechnology 
activity carried out in Canada takes place inside these clusters, usually the few main ones. 
Only 2% of the patents have no assignee6 inside these clusters. These patents are found 
most often in Ontario (19 patents) or Alberta (13 patents). There are very few patents 
(1%) with co-assignees from multiple Canadian clusters. The lack of common inter-
cluster ownership of patents suggests that there is very little cooperation at the assignee 
level between clusters and if there is, ownership of patents is not shared. 
A vast literature exists on how to measure the value of patents. Patent ‘quality’ 
measured by citations (Trajtenberg, 1990), patent family size (Lanjouw et al., 1998), 
patent renewal decisions (Wang et al., 2010), number of claims7 (Lanjouw and 
Schankerman, 2004) or various combinations of these (Bonaccorsi and Thoma, 2007) 
have been used as a proxy for patent value. Tong and Frame (1994), for instance have 
demonstrated that the number of claims is significantly and consistently indicative of 
higher value patents. In their review of the literature, van Zeebroeck and van 
Pottelsberghe de la Potterie (2006) show that the conclusions of most papers on patent 
value find a positive association between patent value and the number of claims. Lanjouw 
and Schankerman (2004) have suggested that specifically in the biotechnology field the 
                                                
6 A patent assignee is an entity (original or legal company, organization or person) that is registered as 
proprietor of the patent or patent application. 
7 Patent claims are a series of numbered expressions describing the invention in technical terms and 
defining the extent of the protection conferred by a patent (the legal scope of the patent). A high number of 
patent claims is an indication that an innovation is broader and has a greater potential profitability. One 
limitation of this study is that we do not have access to patent citations which would allow us to compare 
various patent quality measures. 
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number of claims is the most important indicator of patent quality. Assuming that a 
greater number of claims corresponds to the higher value/quality of a patent, Table 1 
shows that the quality of the patents whose assignee is from the Vancouver or Saskatoon 
clusters is much higher than the quality of other patents. In addition, the patents whose 
owners reside outside the Canadian clusters are observed to have a much higher quality 
on average. 
3.2 Patent ownership structure in Canadian biotechnology clusters 
In order to understand the institutional composition of the biotechnology clusters we 
have examined the ownership of the patents. The patents were divided according to the 
nature of the entity to which they were assigned. Table 2 shows the distribution of the 
patents based on the category of the patent owner.  
(Insert Table 2 here) 
Around half of the patents are assigned solely to companies, much less to universities 
or governmental institutions. Biotechnology is a scientific field with potentially high 
financial revenues, which probably explains the high entrepreneurial interest and 
consequently the high representation of the private sphere among the biotechnology 
assignees. Commercial interests push the private biotechnology companies to strictly 
protect their most important assets, intellectual property, by employing appropriate 
mechanisms (such as patents), whereas the registration of the university or governmental 
inventions at the patenting offices may not seem so crucial to the individual inventors, 
who may not particularly care about the financial well-being of the institution. Moreover, 
the main objective of a university or a research lab is not to make money (in comparison 
with the private company) and the process of intellectual property protection and 
invention commercialization thus may not be given as high an importance.   
Canada has the second highest share of industry-financed research in the academic 
sector among the G7 countries (Germany has the highest score). Industry financed over 
8% of Canadian university R&D activities in 2005 (OECD, 2007). This is suggestive of 
strong linkages between industry and universities, the results of which we however fail to 
observe in our data. In an ideal world, frequent cooperation between firms and 
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universities should be revealed by a higher number of co-assignments of biotechnology 
patents if both universities and industries had equal bargaining power over IP ownership 
negotiations. Only 67 patents were co-assigned to a firm and a university simultaneously, 
which represents only 2% of all patents. We suppose that the particular contractual 
arrangements regarding intellectual property rights between universities and firms are the 
reason why the patents resulting from joint research projects are assigned uniquely to the 
firm or to the university. It is interesting to note that most of the patents jointly owned by 
firms and universities have international co-assignee or co-assignees, residing usually in 
the US. 
Furthermore, patents whose assignees or co-assignees are firms have higher value (as 
measured by the average number of claims for patents in each category) than most of the 
ones whose owners are not companies. The patents of the lowest value are generally 
owned by individuals, usually the inventors themselves.  
Figure 1 shows the proportions of patents assigned to different entities in the most 
common categories. The Toronto cluster possesses the largest (75%) proportion of 
patents assigned to firms. The portion of the Montreal company-owned patents is 
considerably lower (58%). Industrial biotechnology research is highly concentrated in the 
big clusters such as Toronto or Montreal, while university research is spread over the 
small Canadian clusters. The enormous share of the patents in Ottawa assigned to 
government entities strikes at first sight. Ottawa, as the capital of Canada, hosts many 
federal government research institutions producing biotechnology patents. A certain 
number of patents which do not involve any local inventive element and are generated 
outside the Ottawa cluster, are still assigned to, or being represented by, the federal 
institutions in Ottawa, for example the National Research Council, various ministries or 
Her Majesty the Queen (owner of 92 patents, which would make Her Majesty the greatest 
individual biotechnology patent owner in Canada!). The National Research Council of 
Canada has five national biotechnology institutes throughout the country (Montreal, 
Vancouver, Ottawa, Saskatoon and Halifax), but 99% of the patents owned by the 
National Research Council are assigned to its central office in Ottawa. Consequently, the 
patents co-assigned jointly to government and universities suggest non-local cooperation 
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(none of the university co-assignees is located in Ottawa), even though this might not 
necessarily be true. In the case of the governmentally assigned or co-assigned patents we 
were not able to distinguish where the innovative activity in fact took place. 
(Insert Figure 1 here) 
The picture is also blurred by the fact that in some clusters the patents produced by 
university hospitals or hospital research centres affiliated to universities may have been 
assigned to the hospitals themselves, while in other clusters they are assigned directly to 
universities. This probably explains the very high percentage of university patents found 
in clusters in which at the same time there is not a single hospital-assigned patent (as in 
Vancouver, Calgary, Saskatoon, Kingston, Winnipeg and Sherbrooke), while in Toronto, 
there are more patents actually assigned to hospitals than to universities. For instance, in 
Toronto, the Hospital for Sick Children and the Mount Sinai Hospital are both affiliated 
hospitals of the University of Toronto. Hospital researchers hold faculty appointments 
with the university, but patent mostly within the hospitals. Even if we take this fact into 
consideration, the shares of patents assigned to universities in these five clusters are still 
substantial, whereas the portions of the university-owned patents in the Toronto and 
Ottawa clusters are alarmingly low. The differences in university patenting among the 
clusters are possibly related to the distinct intellectual property (IP) rules and policies 
which, in Canada, are governed by the universities themselves. In 2003, 78% of Canadian 
universities actively participated in managing intellectual property, but formal 
requirements to disclose inventions existed only in 45% of universities (Read, 2005). We 
investigated the rules regarding the ownership of the IP rights at the universities with the 
highest numbers of biotechnology patents (see Table 3). In the case where the IP rights 
are owned by an inventor or jointly by both an inventor and a university at the time of 
invention creation, the inventor usually has the option to either commercialize the 
invention himself or assign the IP rights to the university, where a technology transfer 
office will take care of the commercialization process. In many cases the inventions are 
owned by default by the university who decides whether to commercialize the invention 
or not. Table 3 presents the distribution of the net revenue based on whether the 
ownership of the invention is retained by the inventor or by the university. This shows 
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that inventors at various universities have quite diverse opportunities and motivations for 
the commercialization of their inventions. An academic inventor who retains the IP rights 
may consider the patenting of his invention as an expensive, lengthy, risky, drudging and 
usually not particularly profitable process. Furthermore, as publication and not patenting 
is more rewarding in one’s academic carrier, a prolonged patent application process can 
delay the inventor’s ability to publish.8  
(Insert Table 3 here) 
In order to better understand the impact of the IP rights policy on the biotechnology 
patenting at the 13 most prolific Canadian universities, their co-assignees were examined 
in Table 4. The table shows that the co-assignees of the selected universities are usually 
not coming from academia and they are commonly not Canadians.9 However, the 
University of Saskatchewan and Queen’s University follow a distinct pattern, since they 
greatly prefer Canadian co-assignees over international ones. Even though these two 
universities belong among the smallest ones on the list (University of Saskatchewan has 
19 000 students and Queen’s University has 20 000 students), they still largely 
outperform their much bigger counterparts in biotechnology patenting and are in fact 
producers of the great majority of the biotechnology patents in their clusters (see 
Saskatoon and Kingston in Figure 1). The IP rules favouring university ownership could 
be the reason behind their superior patenting in biotechnology (see especially the IP rules 
at University of Saskatchewan in Table 3). Note that at the same time, the levels of patent 
co-assignment (percentage of the university’s owned patents which are co-assigned) at 
both universities are relatively low. In contrast, some of the universities where the 
researchers face clear disincentives to assign the IP rights of their inventions to the 
university (University of Alberta and until recently the University of Toronto) are also 
among the universities with highest levels of co-assignment. It seems that the fact that the 
                                                
8 In Canada, the USA and Mexico an inventor has one year after publishing his invention to file a patent 
application. Nevertheless, in most of the other countries, the novelty of the invention is destroyed by 
publishing an enabling description of the invention before filing for a patent protection. 
9 In fact, in the entire database there are only 11 patents owned jointly by two Canadian universities (this 
represents only 8% of all patents co-assigned with Canadian universities). 
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patent is co-assigned with a firm or another entity counteracts these unfavourable 
incentives. The link between university IP rights policy and patenting propensity is 
therefore unclear. The motivation of inventors lies elsewhere. 
(Insert Table 4 here) 
Table 5 shows the main statistics concerning the assignees of the biotechnology 
patents whose inventors include at least one Canadian inventor. The first column includes 
all categories of assignees, while the second one only counts the assignees recognized as 
private firms. We are aware that our method underestimates the number of biotechnology 
firms, because only those which have at least one biotechnology patent registered at the 
USPTO are considered. Firms may have been left uncounted for various reasons: First, 
this method excludes all the biotech companies that patent solely at different patent 
offices (e.g. CIPO, EPO). The number of such companies is unknown to us, however, 
since Canadian inventors usually do not patent solely in Canada (as explained earlier) we 
assume that the number of patents registered exclusively at the CIPO are not substantial. 
Some of the inventors (particularly those who collaborate with European researchers) 
may nevertheless have chosen to file their patent application both at the CIPO and the 
EPO. Second, it obviously also excludes the firms which do not patent any inventions at 
all. Due to the highly codified nature of biotechnology knowledge, we can presume that 
biotechnology companies would rarely choose not to patent at all as this is one of the 
most appropriate IP protection mechanism for this kind of knowledge. The main focus of 
our research is on innovation and thus the exclusion of a company which does not pursue 
any patentable innovative activity does not change the picture significantly. Third, an 
innovative biotechnology firm will not be included if it prefers (probably for strategic 
reasons) an alternative means of intellectual property protection such as technology 
transfer agreements or licensing.  
(Insert Table 5 here) 
It is interesting to note that in Table 5 the lowest number of assignees (3 assignees) is 
found in the Kingston cluster, which by no means counts among the smallest biotech 
clusters with 63 patents and 94 inventors. An overwhelming majority of the Kingston’s 
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patents are produced at Queen’s University, whose Faculty of Health Sciences is very 
active in biotechnology research. There are in fact only two innovative (in the sense of 
biotechnology patenting) companies in the Kingston cluster. A similar situation exists in 
Saskatoon, with the University of Saskatchewan producing or co-producing almost 80% 
of all the patents. The University of Saskatchewan’s Vaccine and Infectious Disease 
Organization, which develops DNA-enhanced immunization vaccines for both humans 
and animals, is a full or partial owner of all the University of Saskatchewan’ 
biotechnology patents in our database. Saskatoon also hosts the NRC Plant 
Biotechnology institute which may however generate a large portion of its patents 
assigned to the Ottawa NRC head quarters. The “patent per assignee” ratios in the next 
column are thus considerably higher for these two clusters and the “patents per firm” 
ratios are understandably much lower. Toronto and Montreal show quite comparable 
numbers of patents whether measured per assignee or per firm. However, the number of 
patents produced on average by firms in the Vancouver cluster is considerably lower than 
that of the other two major cities. As for the number of inventors per institution, it is 
especially high in Montreal. Calgary and Ottawa are clusters with relatively high 
numbers of patents, which even exceed the number of inventors. Their ratios of patents 
per assignee or patent per firm are consequently also fairly high. This probably means 
that the institutions in these clusters involve a large number of biotechnology researchers 
(e.g. in Ottawa, NRC and Her Majesty the Queen are ranked fourth and fifth as assignees 
with the greatest number of patents), but also that the biotech companies are probably 
larger (as the high ratio of “inventors per assignee” suggests). Otherwise, it could be 
generally stated that smaller clusters have a lower number of patents per institution or per 
firm, implying either that companies in these clusters are on average smaller as well or 
that they are simply patenting less. 
Canadian assignees which are the full or partial owners of more than 20 
biotechnology patents at the USPTO are listed in Table 6. In addition to the information 
on the number of patents, the number of papers in biotechnology is also shown (provided 
by the National Research Council Canada, 2005) for the institutions most active in 
biotechnology. We have already mentioned that the National Research Council of Canada 
possesses five biotechnology related institutes throughout Canada; unfortunately, the 
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assignee is more often than not the main office in Ottawa and as such does not allow a 
regional distinction.  
(Insert Table 6 here) 
Table 6 confirms that biotechnology innovation is strongly based on publicly-funded 
research. Out of the first thirty assignees with the highest number of biotechnology 
patents there are 13 universities, 5 government institutions and 2 hospitals. While part of 
university funding obviously comes from private contracts, the bulk of the money stems 
from public funds. The most important producers of patents are universities with McGill 
University (123 patents) heading the league table. Universities are also unsurprisingly the 
most active institutions in terms of scientific paper production. Here the apparent leader 
is the University of Toronto (533 papers), which however owns a rather low number of 
patents (28 patents) in comparison. This shows again that in spite of the high quality 
research which is conducted at University of Toronto, not many inventions have probably 
reached the hands of the university technology transfer offices, but those of the affiliated 
hospitals. During the last 20 years, the intellectual property policies at the University of 
Toronto did not encourage its inventors to assign their patents to the University. 
Moreover, in many cases, even though the inventors owned all the IP rights, the 
University of Toronto was still engaged in commercialization of their inventions. 
However, the university has recently made many changes into its IP policy, and it 
remains to be seen in the coming years how these changes will be reflected in the number 
of university-assigned patents.10 Other universities with a disproportionately higher 
publication record (in comparison with the number of patents) are Université de Montreal 
and Université Laval, which both have over 200 papers but only 32 patents.  
The contribution of government institutions to the biotechnology research and 
development is also substantial: among the five highest ranking patent holders are the 
National Research Council of Canada11 (95 patents), the Government of Canada’s 
                                                
10 Information gathered during the conversation with the technology transfer office at University of Toronto 
11 Inventors’ addresses will indicate where the research has actually taken pace. 
 20 
premier agency for research and development and Her Majesty the Queen in right of 
Canada (92 patents) usually representing various federal ministries (agriculture, health, 
national defence). The Alberta Research Council, a research agency owned by the 
province of Alberta, holds 34 patents and the agency which was engaged (before it was 
disbanded in the late 1980’s) in commercializing the research performed at government 
labs, the Canadian Patents and Development, possesses 26 patents. The most active 
government institutions in biotechnology research are the National Research Council 
(160 papers) and Agriculture and Agri-Food Canada (191 papers), which is however the 
owner of only 8 patents. 
The Hospital for Sick Children (71 patents and 109 papers) and the Mount Sinai 
Hospital (31 patents and 108 papers), which are both affiliated to the University of 
Toronto, lead the patent league among hospitals. These could explain how patents 
“escape” from the ownership of the University of Toronto. According to the university’s 
IP policies, the patents are usually assigned to the institution where the research takes 
place physically. The university professor who is at the same time a doctor or a 
researcher at one of the university-affiliated hospitals will probably carry out most of his 
research at the hospital, which will thereby become the patent owner12. 
Finally, a number of private companies are also the owners of a considerable number 
of biotechnology patents. The most inventive firms reside mainly in Toronto (e.g. 
Connaught Laboratories, Aventis Pasteurs, Allelix Biopharmaceuticals), but also in 
Montreal (e.g. Merck Frosst Canada, Boehringer Ingelheim Canada) or in Ottawa 
(Adherex). Only the patents registered under the Canadian residence of an assignee are 
counted (this excludes subsidiaries with the same name but with an address outside 
Canada). As expected, the number of papers published by private companies is relatively 
small, since they prefer to protect their assets by patenting rather than revealing them into 
public domain through scientific papers. 
                                                
12 Information gathered during the conversation with the technology transfer office at University of 
Toronto. 
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3.3 Biotechnology field specialization in clusters 
As a next step, we investigated the various biotechnology fields and their 
representation in the database. We grouped various biotechnology fields according to the 
final use of the products into four categories: health-related biotechnology, agriculture 
and food related biotechnology, environmental and industrial biotech, and other 
biotechnology13. We found that health-related biotechnology clearly represents the 
greatest proportion (78%) of all patents in the database, while agriculture and food related 
biotechnology accounts for 10% and environmental and industrial biotech only for 5% of 
all the patents.  
The proportions of the patents of each biotech specialization as granted to assignees 
in the various categories are shown in Figure 2 which shows that the major share of 
patents for all kinds of assignees pertains to health-related biotechnology. Not 
surprisingly, hospitals and other health institutions have a complete focus (100%) on 
health-related biotechnology. The highest proportion (93%) of the health-related biotech 
research is carried out (after hospitals) by the combined firm-university efforts, whereas 
the health biotech patents produced by firms separately or universities separately amount 
only to around 80% of their total biotechnology patent productions. The smallest share of 
health-related biotechnology patents (64%) is granted to the governmental institutions. 
                                                
13 Our definitions of biotech fields are as follows:  
Health-related: human or animal health - pharmaceuticals, diagnostics, therapeutics), bioinformatics (gene 
sequencing, peptide or protein sequence, genomics, gene expressions etc.), nanobiotechnology, devices and 
apparatus specific for the use in health-related biotech;  
Agriculture and food related: plant based agriculture (including fertilizers, manure, composting, 
herbicides and insecticides, etc.), food and edible materials for humans, feeding compositions for animals, 
nutrition (but not with specific therapeutic uses or vitamins, etc., which belong to the health-related 
biotech);  
Environmental and industrial: environmental (biofuels, bioremediation, biodegradation, reutilization or 
destruction of garbage and waste, bioleaching etc.), industrial biotech (processing of metals, production of 
chemicals, other manufacturing processes, etc.), bioprocess technology (biocatalysis, bioseparation, 
biofilter, bioreactor, etc.);  
Other - multiple uses in more than one of the above categories, non-specific biotech lab equipment 
(devices,  apparatus, etc.) or completely other uses (for ex. fingertips in police investigation)  
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These, however, account for a proportionally highest part (20%) of the agriculture and 
food related biotech patents.  Universities are relatively less (8%) interested in doing 
environmental or industrial biotech research. 
(Insert Figure 2 here) 
Figure 3 shows the composition of the biotechnology fields in each cluster. Inside 
clusters, there seems to be an apparent focus on health-related biotechnology, whereas the 
patents produced outside the clusters are as often health as agriculture and food related. 
The highest focus on health-related biotechnology was found in the two most successful 
clusters, which largely disregard the agriculture and food related or environmental and 
industrial biotechnology. In general, the very low shares of patents in agricultural and 
environmental biotech fields are rather surprising, as we expected to find evidence of 
some more specialized clusters (especially agriculture-related biotech in the Prairies – 
e.g. Saskatoon). Niosi (2003) however suggests that biotechnology firms in these fields 
stagnate or are in decline. We observe that the clusters with previously considerable 
shares of R&D in these fields have reoriented themselves towards the more profitable 
sphere of business in health-related products. 
(Insert Figure 3 here) 
 
3.4 Collaboration in Canadian biotechnology based on patent co-assignment 
Finally we examined the collaboration propensity in Canadian biotechnology. In 
order to trace the collaborative relationships among various entities we explored the joint 
ownership of patents, assuming that if a patent lists more than one assignee the invention 
has been developed under the active collaboration of the entities in question. Joint patent 
ownership is therefore considered to be a sign of the cooperation between institutions or 
individuals.14 The analysis of assignments and co-assignments allowed us to understand 
                                                
14 Although we are aware that this represents a very small part of inter-organisation collaboration, and that 
most collaboration does not lead to co-patenting, it is nevertheless a worthwhile exercise. Joint ownership 
of patents was used previously to explore the inter-firm collaborations. For example, in order to investigate 
joint cooperative activities and formation of development coalitions, Gauvin (1995) used data on co-
assignees of the patents granted by the Canadian government, Mariani (2000) examined co-patenting in the 
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the international, inter-cluster and intra-cluster collaborative patterns in biotechnology 
innovation where partners share a ‘similar’ paternity over the innovation. 
Out of 3550 patents comprised in the CI database around 9% are not assigned and 
most of the patents (83%) have a single assignee, which does not provide us with enough 
evidence of collaboration. The remaining patents (8%) are however assigned to several 
entities at the same time (multiple assignees). We examined these patents in more detail 
and specifically looked into the geographical aspect - the residences of the assignees and 
co-assignees. As Table 7 shows, most of the assignees in the database reside solely in 
Canada. Canadian entities are full or partial owners of around 70% of the USPTO 
biotechnology patents with at least one Canadian inventor. In 5% of patents Canadian 
assignees have foreign co-assignees, which is a very small proportion of patents. Most of 
these co-assignees (78%) reside in the USA, followed by France (4%) and Great Britain 
(3%). Also, 21% of patents in the database are fully assigned to a foreign entity, in most 
of these patents (77%) the foreign single assignee is located in the USA as well, followed 
by France (4%). Only very few patents are owned by the multiple assignees among which 
none is located in Canada. 
(Insert Table 7 here) 
With regards to the cooperation within Canada, it has already been shown in Table 1 
that most of the biotechnology activity which takes place in Canada is concentrated 
inside clusters, usually the main ones. We have found only very few patents (1%) with 
co-assignees from multiple Canadian clusters, or from outside these clusters. In addition 
to the very low level of inter-cluster patent ownership, we also observed only a marginal 
number of patents (2%) co-assigned to multiple entities within the clusters themselves. 
(Insert Figure 4 here) 
                                                                                                                                            
European chemical industry. Taking this into consideration, the analysis of co-assigned collaboration 
allows us to examine the sharing of IP rights among partners, which is an indicator of the ‘equal’ 
importance of the contribution of the partners. 
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Based on all these findings we constructed the summarizing collaborative pattern of 
the institutions in Canadian biotechnology innovation. Figure 4 confirms that the amount 
of collaborative links with the US or other countries is surprisingly high in comparison 
with the apparently lacking joint biotechnology research in Canada. These findings 
however are not in agreement with the study of Gauvin (1995) who found that in Canada 
78% of the joint patent ownerships (registered at CIPO) are domestic, while this figure 
would be only 34% for our biotechnology sample. His database however included the 
patents across all the industries, and biotechnology may be a sector with distinct 
collaborative patterns. We plan to proceed with this research in order to shed light on the 
issue. 
4. Conclusions 
Our research confirmed that Canadian biotechnology is geographically highly 
concentrated. The majority of inventors reside in the three largest greater metropolitan 
areas of Toronto, Montreal and Vancouver. These locations therefore appear to be good 
cluster candidates. Several other agglomerations with sizeable patent production (Ottawa, 
Edmonton, Saskatoon, Calgary and Quebec) were identified together with some fairly 
small biotechnology concentrations (Winnipeg, Kingston, Halifax and Sherbrooke). It has 
yet to be demonstrated however whether these smaller agglomerations qualify as clusters 
in the sense that Porter intended. The summary of the various characteristics of the eight 
most important Canadian biotechnology clusters is shown in Table 8. 
(Insert Table 8 here) 
The findings of this paper clearly suggest that biotechnology in Canada emanates 
from publicly-funded research. We observe that universities are the most active 
institutions in Canadian biotechnology and the greatest producers of patents that are of 
high quality on average. They act as anchor tenants by attracting a pool of skilled workers 
and spin off new biotech firms. In small clusters in development, the local university is 
often nearly the only biotech patent producer in the region. In the larger and more mature 
clusters, where many firms are also located, the university’s biotechnology activities 
represent a more modest share of the total biotech research. We also noted that the 
 25 
production of patents is very different among Canadian universities. We believe that this 
is related to two factors: First, it is the existence, quality and effectiveness of the 
technology transfer support present within these universities, consisting of the formal 
legal infrastructure and sufficient funds to file patents. Second, it also depends on the 
university IP rules and policies which stipulate whether the IP ownership is by default 
assigned to the university or may be retained by the individual inventors. As a 
consequence, several renowned research universities that are highly active in 
biotechnology research own only an inferior number of patents. We did not investigate 
these in great details but found no evidence of the latter. The former factor would require 
a survey of academics regarding the efficiency of the technology transfer office of their 
university. The contribution of the government laboratories to the biotechnology research 
and development is also substantial. Around half of the Canadian biotechnology patents 
are owned by private companies. The patents assigned or co-assigned to firms are of 
higher quality than other patents on average. This was for instance found by Beaudry and 
Schiffauerova (2011) in the case of nanotechnology. 
The paper has also examined the composition of biotechnology in Canada. 
Biotechnology related to human health is the most significant biotechnology sector in 
Canada in terms of number of firms, employment, R&D and revenues (Statistics Canada, 
2005). We have confirmed that health-related biotechnology represents by far the highest 
proportion of all biotechnology innovation research in Canada for all the various 
categories of assignees. In addition, the greatest and most successful clusters in Canada 
have a greater focus than the smaller ones on the health-related biotechnology field and 
largely disregard the agriculture and food related or environmental and industrial 
biotechnology. While the focus on the health-related biotechnology fields is 
overwhelmingly inside clusters, outside the clusters, however, the patents produced in 
Canada belong as often to the health related as to the agriculture and food related biotech 
specializations. Firms that focus on other applications than health related thus do not 
seem to benefit from the advantages that come with being located in clusters. This may 
explain the reason of their decline as suggested by Niosi (2003). 
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Based on the patent assignment and co-assignment data we have also constructed the 
intra-cluster, inter-cluster and international collaborative pattern in biotechnology 
innovation. We found very little evidence of cooperation amongst Canadian 
biotechnology institutions from co-assignment, whether the collaborative ties lie within 
or outside clusters. Beaudry and Schiffauerova (2010) showed that 60% of biotechnology 
co-invention (measured at the inventor level) involves inventors from the same ‘cluster’ 
or city, while only 11% involves inter-cluster co-invention in Canada. The three most 
important greater metropolitan areas (i.e. Montreal, Toronto and Vancouver) all have 
intra-cluster co-invention collaboration rates greater than 60% while for other city-
clusters, this proportion declines (Schiffauerova and Beaudry, 2009). The most frequent 
typical partner for a Canadian biotechnology institution with which to pursue joint 
research activities is not a Canadian institution,  but an institution abroad (mainly in the 
US). This contrasts with the implied 29% proportion of international collaboration 
suggested by other studies. While co-patenting across country borders appears more 
important than between Canadian cities, cross-border co-assignment of patents is rather 
rare. Further research is therefore needed on this institutional cooperation. 
Finally, it is not surprising that the inventions are often not owned by their creators. 
We have shown that the fruit of the inventive effort of the researchers is often claimed by 
universities, hospitals or companies. Moreover, although there is a great innovation 
capability among Canadian researchers, a lot of the intellectual property actually leaves 
the country. It has also an important implication for our research. Since the intellectual 
property policies of the various patent-owning institutions throughout the country are 
quite diverse, the information on the patent assignees often does not reveal the whole 
story behind the origin of the invention, its creation and the real innovative productivity 
of the location. Therefore future research should try to reach the roots of the inventive 
effort and focus on the real creators of innovations – the inventors themselves. 
There are a number of limitations to this study. First, the intra-cluster links are not 
formally identified. As a consequence, what we refer to as clusters could simply be 
clusters in the making. Formal collaboration ties between inventors need to be further 
investigated to assess whether the 12 agglomerations identified truly are clusters. Second, 
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our data does not allow the comparison between the quality of the patents produced in 
each of these cities beyond that proxied by claims. Other patent quality measures need to 
be examined. Combining these two limitations with the micro-cluster analysis of 
Aharonson et al. (2008) would allow the identification of the ‘hottest’ clusters in terms of 
patent value. 
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Tables and figures 
 
Table 1: Summary of the results for biotechnology clusters 
Biotechnology 
cluster 
Number of 
patents* 
as  % of all 
patents 
Claims 
(average) 
Number of 
inventors** 
as  % of all 
inventors 
Patents 
per 
inventor*** 
Toronto 834 34% 14.6 927 29% 1.44 
Montreal 466 19% 14.7 698 22% 1.05 
Vancouver 255 10% 19.9 411 13% 0.95 
Edmonton 153 6% 13.1 210 7% 1.21 
Calgary 127 5% 16.8 91 3% 2.19 
Saskatoon 98 4% 20.1 147 5% 1.04 
Winnipeg 33 1% 13.8 77 2% 0.91 
Kingston 63 3% 16.7 94 3% 1.01 
Ottawa 279 11% 15.3 224 7% 1.26 
Quebec 57 2% 15.8 127 4% 0.97 
Halifax 20 1% 16.2 33 1% 1.06 
Sherbrooke 16 1% 13.2 26 1% 1.07 
outside clusters 47 2% 19.4 159 5% 1.16 
co-assignees from 
multiple clusters 37 1% 12.8 - - - 
CANADA Σ 2485 100% 15.6 Σ 3224 100% 1.21 
* The numbers are based on the residence of assignees and only the patents with at least one Canadian 
assignee are thus included (i.e., 753 foreign-assigned patents and 312 non-assigned patents are excluded). 
** Inventors with multiple addresses (who patented while living in several clusters) were assigned to only 
one cluster. 
*** Patents per inventor are counted as the number of patents co-invented by at least one inventor from the 
cluster divided by the number of inventors who at least once patented while living in that cluster. 
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Table 2: Patents by category of assignees 
Assignees’ category Number of patents 
As  % of all 
patents 
Claims 
(average) 
Dominant 
cluster 
firm (single or multiple) 1792 50% 17.0 Toronto 
university (single or multiple) 743 21% 15.7 Montreal 
government*  (single or 
multiple) 338 9% 13.6 
Ottawa 
hospital (single or multiple) 137 4% 13.5 Toronto 
firm-university 67 2% 17.1 Toronto, Montreal 
individual (single or multiple) 25 1% 11.4 Edmonton 
government-university 32 1% 16.2 Ottawa 
hospital-university 33 1% 13.6 Toronto 
other categories** 71 2% 17.38 - 
non-assigned 312 9% 14.4 - 
TOTAL Σ 3550 100% 15.98 - 
* Government assignees include all the federal or provincial laboratories and research institutions, Canadian 
ministries and ministers, Her Majesty the Queen in right of Canada, etc. 
**Includes the following co-assignees categories: firm-government, firm-hospital, firm-hospital-university, 
firm-government-university, government-hospital, firm-individual, hospital-individual, government-
individual, individual-university, hospital-government, hospital-government-university and individual-
firm-hospital-government 
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Table 3: IP ownership and the distribution of the net revenue at the most prolific universities 
patenting in biotechnology in Canada 
IP rights 
ownership 
at the time 
 of invention 
IP rights ownership retained by and/or invention commercialized by 
THE INVENTOR THE UNIVERSITY* 
Distribution of the net revenue: Distribution of the net revenue: 
Inventor University Inventor University 
McGill University Joint 
 
first $100 000: 
  80%, then 70% 
first $100 000:  
 20%, then 30% 
first $10 000:  
100%, then 60% 
first $10 000:  
0%, then 40% 
U. of British Columbia Uni 
   
50% 
 
50% 
 
U. of Saskatchewan Uni 
  
50% 
 
50% 
 
Queen’s University Inv 
 
first $500 000:  
100%, then 75% 
first $500 000:  
0%, then 25% 
negotiated 
 
negotiated 
 
University of Calgary Inv 
 
75%-90% 
 
25%-10% 
 
50% 
 
50% 
 
University of Alberta  Inv 
 
66.6% 
 
33.3% 
 
33.3% 
 
66.6% 
 
University of Guelph Uni 
  
first $100 000: 
 75%, then 25% 
first $100 000:  
25%, then 75% 
Université de Montreal Inv 
 
negotiated 
 
negotiated 
 
negotiated 
 
negotiated 
 
Université Laval Uni 
   
50% 
 
50% 
 
University of Toronto Joint 
 
75% 
 
25% 
 
60% 
 
40% 
 
University of Ottawa Uni 
   
first $100 000:  
80%, then 50% 
first $100 000:  
20%, then 50% 
University of Manitoba Joint 
 
negotiated 
 
negotiated 
 
negotiated 
 
negotiated 
 
University of Victoria Inv 
 
if <$5,000/year:  
 100%, else 80% 
if <$5,000/year:  
0%, else 20% 
negotiated 
 
negotiated 
 
* Some universities have founded special non-for-profit organizations in order to commercialize the IP of 
the university-generated research. These organizations may have exclusive rights to the university IP. 
However, we do not distinguish here whether the invention is owned and/or commercialized directly by the 
university or by this organization. 
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Table 4: Patents co-assigned with universities most prolific in biotechnology patenting in Canada 
 University co-assignee Non-university co-assignee All co-
assigned 
patents  
 
All 
patents  
 
Canadian 
Non- 
Canadian 
Canadian Non- 
Canadian Firm Govern. Hosp. 
McGill University - 8 5 - 4 9 26 123 
U. of British Columbia 2 8 3 2 - 2 17 114 
U. of Saskatchewan 2 - 7 - - 3 12 78 
Queen’s University - - 1 2 - - 3 61 
University of Calgary 1 8 2 - - - 11 59 
University of Alberta 1 4 3 1 - 5 14 57 
University of Guelph 2 2 - 2 - 1 7 35 
Université de Montréal - 4 - 1 1 1 7 32 
Université Laval - - 1 2 - 1 4 32 
University of Toronto - 2 2 1 3 1 9 28 
University of Ottawa - - - 3 - 5 8 26 
University of Manitoba 1 3 1 1 - - 6 22 
University of Victoria - - - - - - - 20 
 
Table 5: Results regarding assignees as counted per biotechnology cluster 
Biotechnology 
cluster 
Number of 
assignees 
Number of 
firms* 
Patents per 
assignee 
Patents per 
firm** 
Inventors per 
assignee*** 
Toronto 144 110 5.79 5.38 6.44 
Montreal 77 55 6.05 4.80 9.06 
Vancouver 51 44 5.00 2.70 8.06 
Edmonton 29 19 5.28 2.89 7.24 
Calgary 13 11 9.77 6.18 7.00 
Saskatoon 9 6 10.89 2.50 16.33 
Winnipeg 9 7 3.67 1.71 8.56 
Kingston 3 2 21.00 2.00 31.33 
Ottawa 28 11 9.96 5.00 8.00 
Quebec 18 11 3.17 1.82 7.06 
Halifax 5 3 4.00 2.67 6.60 
Sherbrooke 4 2 4.00 1.50 6.50 
outside clusters 28 18 1.68 1.33 5.68 
CANADA Σ 418 Σ 299 5.86 4.10 7.71 
* Only inventive firms (i.e. those which have produced at least one biotechnology patent) are counted. 
** Number of patents assigned to firms divided by the number of inventive firms in the cluster. 
*** Number of all inventors divided by the number of assignees in the cluster. 
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Table 6: Assignees with Canadian residence with 20 or more patents filed with the USPTO 
Assignee 
Number 
of 
patents 
Number 
of 
papers* 
Cluster Province Assignee’s category 
1 McGill University 123 372 Montreal QC university 
2 Connaught Laboratories Ltd 118  Toronto ON firm 
3 University of British Columbia 114 308 Vancouver BC university 
4 National Research Council of Canada 95 160 Ottawa ON government 
5 Her Majesty the Queen of Canada 92  Ottawa ON government 
6 University of Saskatchewan 78 170 Saskatoon SK university 
7 Hospital for Sick Children 71 109 Toronto ON hospital 
8 Aventis Pasteur Ltd 63 13 Toronto ON firm 
9 Queen’s University 61  Kingston ON university 
10 University of Calgary 59 189 Calgary AB university 
11 University of Alberta 57 244 Edmonton AB university 
12 Allelix Biopharmaceutical 52  Toronto ON firm 
13 Merck Frosst Canada Inc. 42 14 Montreal QC firm 
14 Visible Genetics Inc 40  Toronto ON firm 
15 University of Guelph 35 223 Toronto ON university 
16 Alberta Research Council 34  Edmonton AB government 
17 Université de Montreal 32 209 Montreal QC university 
18 Université Laval 32 205 Quebec QC university 
19 Syn X Pharma 32  Toronto ON firm 
20 Mount Sinai Hospital 31 108 Toronto ON hospital 
21 University of Toronto 28 533 Toronto ON university 
22 University of Ottawa 26  Ottawa ON university 
23 Canadian Patents and Development  26  Ottawa ON government 
24 Boehringer Ingelheim Canada Ltd 26  Montreal QC firm 
25 Adherex 25  Ottawa ON firm 
26 University of Manitoba 22  Winnipeg MB university 
27 NPS Allelix Corp. 22  Toronto ON firm 
28 Spectral Diagnostics Inc. 21  Toronto ON firm 
29 Ontario Cancer Institute 21  Toronto ON Hospital 
30 University of Victoria 20  Vancouver BC university 
* Source: National Research Council (2005). Information is provided only where available. 
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Table 7: Patents by country of the assignees’ residences 
Assignees' residences number of patents 
as  % of all 
patents 
claims 
(average) 
Only Canadian assignees 2310 65% 15.6 
Foreign coassignees of Canadians 175 5% 16.0 
Foreign single assignees 746 21% 17.7 
Foreign multiple assignees 7 0.2% 16.0 
No assignee 312 9% 14.4 
All patents Σ 3550 100% 16.0 
 
Table 8: Summary of information on the seven most important clusters 
 Toronto Montreal Vancouver Ottawa Edmonton Calgary Sask. Quebec 
# of patents 834 466 255 279 153 127 98 57 
# of inventors 927 698 411 224 210 91 147 127 
# of innovative firms 110 55 44 11 19 11 6 11 
Patent quality   v. high   high v. high high 
Firms’ innovative 
productivity   low  low v. high low low 
Inventors’ innovative 
productivity high    high v. high   
% of health-related biotech 89% 91% 80% 63% 86% 76% 88% 77% 
         
Patent 
ownership 
structure 
Firms 70% 56% 46% 19% 34% 52% 14% 30% 
Universities 10% 29% 47% 7% 30% 44% 67% 41% 
other (if  
share > 
10%) 
11% 
hosp.   
62% 
gov. 
21% 
gov.   
11% 
gov. 
          
# of prolific* firms 7 2  1     
# of highly prolific** 
universities  1 1  1 1 1  
# of prolific* hospitals 3        
# of prolific* gov. 
institutions 1   3 1    
* Prolific means here that the number of patents of the assignee is > 20 patents. 
** Highly prolific means here that the number of patents of the assignee is > 50. 
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Figure 1: Shares of patents assigned to the various entities in each cluster (the number in parentheses 
shows the total number of patents in the cluster) 
 
 
 
Figure 2: Proportions of patents by biotechnology field as granted to assignees in each category 
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Figure 3: Biotechnology field composition of patents in each cluster 
 
 
 
Figure 4: Collaboration pattern of Canadian biotechnology institutions as evidenced by the patent 
co-assignment  
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